Recent performance snapshot for Acadia Healthcare Company (ACHC)
Acadia Healthcare Company (ACHC) has caught investor attention after a mixed stretch, with the stock down about 17% over the past month but up around 38% over the past 3 months.
See our latest analysis for Acadia Healthcare Company.
With the share price now at $23.18, Acadia Healthcare Company’s recent 7 day share price return of down 10.19% and 30 day share price return of down 17.24% contrast with its stronger 90 day share price return of 38.06% and year to date share price return of 62.21%. Longer term total shareholder returns over 3 and 5 years remain deeply negative, suggesting recent positive momentum is still rebuilding confidence after a difficult few years.
If Acadia’s recent moves have you thinking about where care and technology intersect next, it could be a good moment to scan a curated list of 34 healthcare AI stocks
With Acadia Healthcare’s share price pulled back from recent highs but still well above where it started the year, the key question is whether the current valuation leaves a margin of safety or if the market is already pricing in future growth.
Most Popular Narrative: 94.1% Overvalued
According to the most followed narrative, Acadia Healthcare Company’s fair value is $11.94, which sits well below the last close at $23.18. This sets up a clear tension between model and market.
This is not a high-growth technology story. It is a capacity-and-execution story in a market where demand is persistent and under-supplied. If Acadia continues to expand responsibly while maintaining care quality, its relevance is likely to increase rather than fade.
Curious what kind of revenue trajectory and profit turnaround would justify almost halving today’s price? The narrative leans heavily on profitability inflection, margin rebuilding, and a disciplined growth path that is anything but conservative.
Result: Fair Value of $11.94 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to watch for risks such as persistent net losses of $1,107.041 million or tighter reimbursement policies that could pressure margins and reinvestment plans.
Find out about the key risks to this Acadia Healthcare Company narrative.
Another valuation angle: cash flows tell a different story
While the popular narrative tags Acadia Healthcare Company as 94.1% overvalued at a fair value of $11.94, our DCF model points the other way. It indicates an estimated future cash flow value of $82.89 per share versus a market price of $23.18. Which set of assumptions do you find more convincing?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
With such a sharp split between risk and reward narratives, this is a moment to move quickly, review the data and shape your own view using our breakdown of 3 key rewards and 1 important warning sign.
Looking for more investment ideas?
If you stop with just one stock, you could miss out on opportunities that better fit your goals, risk comfort and time horizon.
- Spot potential bargains early by scanning for strong businesses trading below what their fundamentals might justify using the 49 high quality undervalued stocks.
- Prioritize resilience by focusing on companies with healthier finances through the solid balance sheet and fundamentals stocks screener (46 results).
- Hunt for overlooked opportunities that others might be ignoring with the screener containing 21 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com